Home » Stocks » Sunesis Pharmaceuticals

Sunesis Pharmaceuticals, Inc. (SNSS)

Stock Price: $0.313 USD 0.013 (4.30%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $0.322 +0.009 (2.88%) Aug 7, 4:38 PM

Stock Price Chart

Key Info

Market Cap 51.18M
Revenue (ttm) 2.19M
Net Income (ttm) -23.25M
Shares Out 111.39M
EPS (ttm) -0.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $0.313
Previous Close $0.300
Change ($) 0.013
Change (%) 4.30%
Day's Open 0.300
Day's Range 0.290 - 0.320
Day's Volume 18,478,042
52-Week Range 0.195 - 1.130

More Stats

Market Cap 51.18M
Enterprise Value 28.41M
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 111.39M
Float 80.89M
EPS (basic) -0.24
EPS (diluted) -0.23
FCF / Share -0.20
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.93M
Short Ratio 0.34
Short % of Float 2.85%
Beta 1.86
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 23.34
PB Ratio 3.21
Revenue 2.19M
Operating Income -23.40M
Net Income -23.25M
Free Cash Flow -21.82M
Net Cash 22.77M
Net Cash / Share 0.14
Gross Margin 94.53%
Operating Margin -1,066.99%
Profit Margin -1,060.00%
FCF Margin -994.80%
ROA -49.37%
ROE -118.68%
ROIC -253.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 0
Overweight 0
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$0.75*
(139.69% upside)
Low
0.50
Current: $0.313
High
1.00
Target: 0.75
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue2.070.240.672.543.065.737.963.755.000.03
Revenue Growth774.68%-64.57%-73.62%-17.15%-46.62%-27.93%111.93%-24.92%15051.52%-
Gross Profit2.070.240.672.543.065.737.963.755.000.03
Operating Income-23.29-25.71-34.42-36.46-39.30-45.04-31.77-34.61-25.87-21.41
Net Income-23.33-26.62-35.46-38.02-36.68-43.00-34.60-43.95-20.14-24.59
Shares Outstanding87.1335.5824.5215.6912.1610.018.718.027.744.14
Earnings Per Share-0.27-0.75-1.45-2.42-3.02-4.57-3.96-5.46-2.58-5.94
Operating Cash Flow-22.19-24.40-36.14-36.96-38.73-43.18-37.42-10.64-22.84-19.38
Capital Expenditures---0.03---0.05-0.010.020.04
Free Cash Flow-22.19-24.40-36.17-36.96-38.73-43.23-37.42-10.63-22.82-19.34
Cash & Equivalents34.6313.7031.7542.5946.4342.9839.2971.2344.1253.40
Total Debt6.287.407.2014.447.839.2618.0424.269.45-
Net Cash / Debt28.346.3024.5528.1538.6033.7221.2546.9734.6653.40
Assets37.2415.3234.3343.2347.0044.2540.5373.0245.8754.86
Liabilities9.7011.3312.7922.2119.6130.4446.7161.0617.8512.61
Book Value27.543.9921.5421.0227.3913.80-6.1811.9628.0242.25
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Sunesis Pharmaceuticals, Inc.
Country United States
Employees 24
CEO Dayton Misfeldt

Stock Information

Ticker Symbol SNSS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SNSS
IPO Date September 27, 2005

Description

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.